TNFRSF8 and cancer: Brentuximab vedotin is an antibody–drug conjugate (ADC) combining CD30 mAb with the microtubule inhibitor monomethylauristatin E. After ligation of ADC with CD30 on the surface of cancer cells, monomethylauristatin E binds to tubulin and disrupts the microtubule network in the cell, resulting in cell cycle arrest and apoptosis [66, 67].